These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32748963)

  • 41. Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility.
    Al-Riyami AZ; Estcourt L; Rahimi-Levene N; Bloch EM; Goel R; Tiberghien P; Thibert JB; Bruun MT; Devine DV; Gammon RR; Wendel S; Toungouz Nevessignsky M; Grubovic Rastvorceva RM; Oreh A; Romon I; van den Berg K; Kitazawa J; Patidar G; So-Osman C; Wood EM;
    Vox Sang; 2022 Oct; 117(10):1202-1210. PubMed ID: 36102139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
    Fabricius MM; Dandachi D
    Mo Med; 2021; 118(1):74-80. PubMed ID: 33551490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
    De Santis GC; Oliveira LC; Garibaldi PMM; Almado CEL; Croda J; Arcanjo GGA; Oliveira ÉAF; Tonacio AC; Langhi DM; Bordin JO; Gilio RN; Palma LC; Santos EV; Haddad SK; Prado BPA; Pontelli MC; Gomes R; Miranda CH; Auxiliadora Martins M; Covas DT; Arruda E; Fonseca BAL; Calado RT
    Emerg Infect Dis; 2022 Mar; 28(3):548-555. PubMed ID: 35081022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors.
    Grujić J; Bujandrić N; Budakov-Obradović Z; Dolinaj V; Bogdan D; Savić N; Cabezas-Cruz A; Mijatović D; Simin V; Anđelić N; Banović P
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.
    Casadevall A; Dragotakes Q; Johnson PW; Senefeld JW; Klassen SA; Wright RS; Joyner MJ; Paneth N; Carter RE
    Elife; 2021 Jun; 10():. PubMed ID: 34085928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors.
    Vinkenoog M; Steenhuis M; Brinke AT; van Hasselt JGC; Janssen MP; van Leeuwen M; Swaneveld FH; Vrielink H; van de Watering L; Quee F; van den Hurk K; Rispens T; Hogema B; van der Schoot CE
    Front Immunol; 2022; 13():821721. PubMed ID: 35296077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [COVID-19 - BLOOD GROUPS, ANTIBODIES AND CONVALESCENT PLASMA].
    Izak M; Yahalom V; Maor Y; Zimhoni O; Cohen D; Chen J; Shinar E
    Harefuah; 2021 Mar; 160(3):139-143. PubMed ID: 33749174
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.
    Nguyen FT; van den Akker T; Lally K; Lam H; Lenskaya V; Liu STH; Bouvier NM; Aberg JA; Rodriguez D; Krammer F; Strauss D; Shaz BH; Rudon L; Galdon P; Jhang JS; Arinsburg SA; Baine I;
    Transfusion; 2021 Jan; 61(1):78-93. PubMed ID: 33125158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Effective Model for Establishing a Collaborative for the Treatment of COVID-19 in the Rio Grande Valley.
    Betancourt-Garcia MM; Arauco-Brown AR; Garcia R; Rosenbaum-Marinaro L; Stutz T; Rao S
    J Health Care Poor Underserved; 2021; 32(3):1276-1287. PubMed ID: 34421030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?
    Focosi D; Franchini M; Joyner MJ; Casadevall A
    Vox Sang; 2022 May; 117(5):641-646. PubMed ID: 35023163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.
    Zhou CK; Bennett MM; Villa CH; Hammonds KP; Lu Y; Ettlinger J; Priest EL; Gottlieb RL; Davis S; Mays E; Clarke TC; Shoaibi A; Wong HL; Anderson SA; Kelly RJ
    PLoS One; 2022; 17(8):e0273223. PubMed ID: 35980913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
    Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
    Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 convalescent plasma donors: Unique motivations in unique times?
    Crowder LA; Steele WR; Goodhue E; Lasky B; Young PP
    Transfusion; 2023 Apr; 63(4):703-710. PubMed ID: 36866426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.